Edward Cha
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 35
- Colorectal Cancer Treatments and Studies 11
- CAR-T cell therapy research 8
- Pancreatic and Hepatic Oncology Research 5
- Immunology top 5%
- Immunotherapy and Immune Responses 11
-
- Advanced Breast Cancer Therapies 5
- Hepatology top 10%
-
- Melanoma and MAPK Pathways 5
-
- Monoclonal and Polyclonal Antibodies Research 5
- Co-authors
- Lawrence FongChristian SchindlerChristopher Y. ParkMalek FahamMark KlingerYafei HouAntoni RibasCraig Cummings
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Journal of Clinical Oncology (17 papers)Annals of Oncology (7 papers)Cancer Research (5 papers)
- Partner nations
- United StatesSouth KoreaChina
In The Last Decade
Edward Cha
53 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 1.3k
- Immunology 776
- Cancer Research 156
- Pulmonary and Respiratory Medicine 275
- Hepatology 65
Countries citing papers authored by Edward Cha
This map shows the geographic impact of Edward Cha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Cha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Cha more than expected).
Fields of papers citing papers by Edward Cha
This network shows the impact of papers produced by Edward Cha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Cha. The network helps show where Edward Cha may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Edward Cha, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, studybreakdown → | 2025 | 26 |
| 5 | 2024 | 35 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 22 | |
| 8 | 2023 | 8 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 37 | |
| 11 | 2022 | 20 | |
| 12 | 2016 | 5 | |
| 13 | 2016 | 26 | |
| 14 | 2016 | 6 | |
| 15 | 2016 | 7 | |
| 16 | 2014 | 3 | |
| 17 | 2012 | 33 | |
| 18 | 2012 | 41 | |
| 19 | 2007 | 20 | |
| 20 | 2000 | 308 |
About Edward Cha
Edward Cha is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 56 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (35 papers), Colorectal Cancer Treatments and Studies (11 papers), Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (8 papers), Advanced Breast Cancer Therapies (5 papers), Melanoma and MAPK Pathways (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (776 citations) and Cancer Research (156 citations). Edward Cha has collaborated with scholars based in United States, South Korea and China. Frequent co-authors include Lawrence Fong, Christian Schindler, Christopher Y. Park, Malek Faham, Mark Klinger, Yafei Hou, Antoni Ribas, Craig Cummings, Jeffrey J. Wallin and Jeffrey R. Infante. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, The Lancet Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.